Work

Supplementary Figure S4 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure S4. EphA2 inhibitors suppressed the viability of VEM sensitive and resistant BRAF mutant cell lines and NRAS mutant cell lines.

DOI: 10.1158/2159-8290.22529609.v1

Authors: Benchun Miao, Zhenyu Ji, Li Tan, Michael Taylor, Jianming Zhang, Hwan Geun Choi, Dennie T. Frederick, Raj Kumar, Jennifer A. Wargo, Keith T. Flaherty, Nathanael S. Gray, Hensin Tsao

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362626525

Cites:

Cited by:

Related to: 10